Literature DB >> 2174737

Interaction of vasopressin and oxytocin with human breast carcinoma cells.

A H Taylor1, V T Ang, J S Jenkins, J J Silverlight, R C Coombes, Y A Luqmani.   

Abstract

The arginine vasopressin and oxytocin content of normal and cancerous human breast tissue were measured using radioimmunoassay. Both peptides were present in amounts greater than that found in the circulation, but no difference between normal and malignant tissues was found. Binding of [3H]oxytocin and [3H]vasopressin were characterized in human breast carcinoma cells (MCF7 cells). Binding of both hormones to MCF7 cells was specific and saturable, the vasopressin receptor found to be of the V1 subtype. Scatchard analyses of the data were linear, indicating a single high affinity, low capacity binding site for each hormone (vasopressin: KD = 47.4 +/- 1.6 nmol/liter, Bmax = 27,300 +/- 6,500 sites/cell; oxytocin: KD = 51.3 +/- 0.4 nmol/liter, Bmax = 87,000 +/- 4,000 sites/cell). The effects of vasopressin and oxytocin on the growth of MCF7 cells were assessed using protein accumulation and cell numbers. Vasopressin at 10-1000 pmol/liter was mitogenic for MCF7 cells, but higher doses (10 nmol/liter) were growth inhibitory. Oxytocin was also mitogenic for MCF7 cells but to a lesser extent than vasopressin. In conclusion, we suggest that vasopressin and possibly oxytocin may be important modulators of the growth of some human breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174737

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.

Authors:  D J Brennan; D P O'Connor; H Laursen; S F McGee; S McCarthy; R Zagozdzon; E Rexhepaj; A C Culhane; F M Martin; M J Duffy; G Landberg; L Ryden; S M Hewitt; M J Kuhar; R Bernards; R C Millikan; J P Crown; K Jirström; W M Gallagher
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

2.  Native MAG-1 antibody almost destroys human breast cancer xenografts.

Authors:  William G North; Roy H L Pang; Guohong Gao; Vincent A Memoli; Bernard F Cole
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

3.  Oxytocin and oxytocin receptor alterations, decreased survival, and increased chemoresistance in patients with pancreatic cancer.

Authors:  Trisheena Harricharran; Olorunseun O Ogunwobi
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2019-12-14

4.  Oxytocin stimulates secretory processes in lactating rabbit mammary epithelial cells.

Authors:  Vanessa Lollivier; Pierre-Guy Marnet; Serge Delpal; Dominique Rainteau; Caroline Achard; Aline Rabot; Michèle Ollivier-Bousquet
Journal:  J Physiol       Date:  2005-09-15       Impact factor: 5.182

Review 5.  Neuroendocrine influences on cancer biology.

Authors:  Premal H Thaker; Anil K Sood
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

6.  The effects of TGF-alpha and 17 beta-estradiol on polyphosphoinositide metabolism in MCF-7 breast cancer cells.

Authors:  R N Etindi; A Manni; J Martel
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 7.  Neurohypophyseal peptides as regulators of growth and development. A review.

Authors:  D A Carter; C K Fai; D Murphy
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

8.  Vasopressin gene related products are markers of human breast cancer.

Authors:  W G North; S Pai; A Friedmann; X Yu; M Fay; V Memoli
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

9.  Oxytocin inhibits proliferation of human breast cancer cell lines.

Authors:  P Cassoni; A Sapino; F Negro; G Bussolati
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium.

Authors:  A Jovanović; L Grbović; I Zikić; I Tulic
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.